Cytokinetics | CYTK - Sales Revenues

Stock Price
65.48
Daily Change
0.54 0.83%
Monthly
4.90%
Yearly
89.41%
Q2 Forecast
64.72

Cytokinetics reported $17.76M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 284M 5.4M Dec/2025
Amgen USD 9.9B 340M Dec/2025
Arca Biopharma 0 0 Mar/2025
Bayer EUR 11.44B 1.78B Dec/2025
Biogen USD 2.28B 250M Dec/2025
Brainstorm Cell Therapeutics 0 0 Mar/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Capricor Therapeutics USD 11.13M 8.87M Dec/2024
Cytokinetics USD 17.76M 15.83M Dec/2025
Eisai JPY 219.94B 22.58B Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Exelixis USD 598.66M 860K Dec/2025
Geron USD 48.02M 820K Dec/2025
Halozyme Therapeutics USD 451.76M 97.76M Dec/2025
Ionis Pharmaceuticals USD 203M 46M Dec/2025
Ligand Pharmaceuticals USD 59.66M 55.8M Dec/2025
Merck USD 16.4B 880M Dec/2025
Novartis USD 13.86B 50M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 11.3B 1.13B Dec/2025